Aquatic Capital Management LLC Lowers Stake in AxoGen, Inc. (NASDAQ:AXGN)

Aquatic Capital Management LLC lessened its stake in AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 74.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,220 shares of the medical equipment provider's stock after selling 35,680 shares during the period. Aquatic Capital Management LLC's holdings in AxoGen were worth $201,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its position in shares of AxoGen by 13.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 772,752 shares of the medical equipment provider's stock worth $12,735,000 after acquiring an additional 91,984 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of AxoGen by 2,912.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 549,000 shares of the medical equipment provider's stock worth $7,697,000 after buying an additional 530,775 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of AxoGen by 14.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 416,610 shares of the medical equipment provider's stock worth $6,866,000 after buying an additional 52,846 shares in the last quarter. Oberweis Asset Management Inc. increased its stake in shares of AxoGen by 31.8% during the fourth quarter. Oberweis Asset Management Inc. now owns 300,500 shares of the medical equipment provider's stock valued at $4,952,000 after buying an additional 72,500 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of AxoGen in the fourth quarter valued at about $4,552,000. Institutional investors own 80.29% of the company's stock.

Wall Street Analyst Weigh In

AXGN has been the topic of a number of research reports. Cantor Fitzgerald reissued an "overweight" rating and set a $24.00 target price on shares of AxoGen in a research report on Wednesday, March 5th. Canaccord Genuity Group lifted their price objective on shares of AxoGen from $22.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday, February 26th. Finally, Lake Street Capital began coverage on AxoGen in a report on Monday, March 17th. They set a "buy" rating and a $30.00 target price for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat, AxoGen currently has a consensus rating of "Buy" and a consensus target price of $22.60.

Insiders Place Their Bets

In other AxoGen news, Director Amy Mcbride Wendell sold 5,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $20.02, for a total value of $100,100.00. Following the completion of the sale, the director now owns 97,899 shares of the company's stock, valued at approximately $1,959,937.98. This trade represents a 4.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Erick Wayne Devinney sold 15,111 shares of the company's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total transaction of $264,442.50. Following the transaction, the insider now owns 217,762 shares in the company, valued at approximately $3,810,835. This trade represents a 6.49 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company's stock.

AxoGen Trading Up 3.9 %

NASDAQ AXGN opened at $17.13 on Monday. AxoGen, Inc. has a 52 week low of $5.55 and a 52 week high of $21.00. The company has a 50 day moving average price of $17.21 and a 200 day moving average price of $16.28. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The firm has a market cap of $759.61 million, a PE ratio of -53.53 and a beta of 1.19.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.